◀ Back to IL2

CXCR3 — IL2

Text-mined interactions from Literome

Pan et al., J Immunol 2006 (Carcinoma, Renal Cell...) : We found that systemic IL-2 induced the expression of CXCR3 on circulating mononuclear cells but impaired the CXCR3 ligand chemotactic gradient from plasma to tumor by increasing circulating CXCR3 ligand levels in a murine model of RCC
Reckamp et al., J Immunother 2007 (Carcinoma, Renal Cell...) : CXCR3 is also associated with antiangiogenic effects in multiple tumors, and we hypothesized that interleukin-2 (IL-2) treatment of patients with metastatic clear cell RCC could augment CXCR3 levels on circulating mononuclear cells and correlate to outcome
Schmitz et al., Brain Behav Immun 2013 : Oppositely, CXCR3-deficiency had no protective effect after traumatic nerve injury but reduced EAE evoked hyperalgesia and was associated with reduced clinical EAE scores, a reduction of the pro-inflammatory cell infiltration and reduced upregulation of interferon gamma and interleukin-17 in the spinal cord